Voloridge Investment Management
HZNP

Voloridge Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Voloridge Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-79,737
Closed -$8.2M – 1670
2023
Q2 		$8.2M Sell
79,737
-31,983
-29% -$3.37M 0.04% 521
2023
Q1 		$12.2M Buy
111,720
+96,398
+629% +$10.7M 0.06% 400
2022
Q4 		$1.74M Sell
15,322
-354,746
-96% -$29.5M 0.01% 999
2022
Q3 		$22.9M Buy
370,068
+301,367
+439% +$21.1M 0.12% 234
2022
Q2 		$5.48M Sell
68,701
-28,994
-30% -$2.75M 0.03% 640
2022
Q1 		$10.3M Buy
+97,695
New +$9.52M 0.06% 402
2021
Q4 		– Sell
-23,578
Closed -$2.58M – 1960
2021
Q3 		$2.58M Sell
23,578
-36,563
-61% -$3.8M 0.02% 958
2021
Q2 		$5.63M Buy
+60,141
New +$5.53M 0.04% 597
2021
Q1 		– Sell
-170,355
Closed -$12.5M – 1769
2020
Q4 		$12.5M Sell
170,355
-147,725
-46% -$11M 0.1% 228
2020
Q3 		$24.7M Sell
318,080
-136,728
-30% -$9.41M 0.21% 122
2020
Q2 		$25.3M Buy
454,808
+225,167
+98% +$9.63M 0.29% 68
2020
Q1 		$6.8M Buy
229,641
+40,652
+22% +$1.38M 0.2% 116
2019
Q4 		$6.84M Buy
188,989
+137,393
+266% +$4.21M 0.13% 196
2019
Q3 		$1.41M Buy
51,596
+42,344
+458% +$1.09M 0.02% 554
2019
Q2 		$223K Sell
9,252
-116,776
-93% -$2.96M 0.01% 690
2019
Q1 		$3.33M Buy
126,028
+70,376
+126% +$1.67M 0.1% 196
2018
Q4 		$1.09M Buy
+55,652
New +$1.09M 0.05% 263
2018
Q3 		– Sell
-137,219
Closed -$2.27M – 526
2018
Q2 		$2.27M Buy
+137,219
New +$2.09M 0.06% 264
2017
Q2 		– Sell
-108,893
Closed -$1.61M – 648
2017
Q1 		$1.61M Buy
+108,893
New +$1.76M 0.04% 342
2016
Q3 		– Sell
-39,175
Closed -$645K – 372
2016
Q2 		$645K Buy
+39,175
New +$634K 0.02% 247
2015
Q4 		– Sell
-78,389
Closed -$1.55M – 356
2015
Q3 		$1.55M Buy
+78,389
New +$2.48M 0.07% 194
2014
Q2 		– Sell
-68,458
Closed -$1.03M – 124
2014
Q1 		$1.03M Buy
+68,458
New +$773K 0.15% 61

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Voloridge Investment Management's HZNP Position: Q3 2023 in Review

Voloridge Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 79,737 shares — an estimated $8.2M sold.

Voloridge Investment Management first reported a position in HZNP in Q1 2014 and held it in 22 quarters. The position peaked at $25.3M in Q2 2020. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Voloridge Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 79,737 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $8.2M.
  • Voloridge Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 22 quarters.
  • Voloridge Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $25.3M in Q2 2020.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Voloridge Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.